Carisbamate
Carisbamate (YKP 509, proposed trade name Comfyde) is an experimental anticonvulsant drug under development by Johnson & Johnson Pharmaceutical Research and Development. In 1998, the compound was in-licensed from SK Corp. (currently Life Science Business Division of SK Holdings), a South Korean company. A phase II clinical trial in the treatment of partial seizures demonstrated that the compound has efficacy in the treatment of partial seizures and a good safety profile. Since late 2006, the compound has been undergoing a large multicenter phase III clinical trial for the treatment of partial seizures. Its mechanism of action is unknown.
Wikipage redirect
primaryTopic
Carisbamate
Carisbamate (YKP 509, proposed trade name Comfyde) is an experimental anticonvulsant drug under development by Johnson & Johnson Pharmaceutical Research and Development. In 1998, the compound was in-licensed from SK Corp. (currently Life Science Business Division of SK Holdings), a South Korean company. A phase II clinical trial in the treatment of partial seizures demonstrated that the compound has efficacy in the treatment of partial seizures and a good safety profile. Since late 2006, the compound has been undergoing a large multicenter phase III clinical trial for the treatment of partial seizures. Its mechanism of action is unknown.
has abstract
Carisbamate (YKP 509, proposed ...... ted at doses up to 600 mg/day.
@en
ATC prefix
ATC suffix
CAS number
194085-75-1
FDA UNII code
P7725I9V3Z
IUPAC name
(S)-2-O-carbamoyl-1-o-chlorophenyl-ethanol
@en
PubChem
thumbnail
Wikipage page ID
10,600,394
Wikipage revision ID
721,935,496
ChEMBL
ChemSpiderID
molecular weight
2.15633e+2
smiles
Clc1ccccc1[C@@H]COCN
StdInChIKey
OLBWFRRUHYQABZ-QMMMGPOBSA-N
Verifiedfields
verifiedrevid
447,761,334
subject
hypernym
comment
Carisbamate (YKP 509, proposed ...... echanism of action is unknown.
@en
label
Carisbamate
@en
